ADAlessandro Landskron Diniz

Alessandro Landskron Diniz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Landskron Diniz has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    O tamanho por si só não basta: Ki-67 e padrões de invasão identificam tumores neuroendócrinos pancreáticos de alto risco

    by Dante Altenfelder Silva Mesquita Cortelli, Silvio Melo Torres, Igor Correia de Farias, Alessandro Landskron Diniz, Heber Salvador de Castro Ribeiro, André Luis de Godoy, Caroline Almeida Gonçalves, Felipe José Fernández Coimbra

    Background: Pancreatic neuroendocrine tumors (pNETS) constitute a heterogeneous and rare disease worldwide. Diagnosis has been increasing, and the evaluation of prognostic factors has become even more important in the treatment decision process. Aims: To present results and prognostic factors in patients undergoing surgical treatment for pNETS in a single Brazilian center.

  • Open Access

    PREVENTION, SURVEILLANCE, AND EARLY DETECTION OF HEPATOCELLULAR CARCINOMA – A BRAZILIAN MULTIDISCIPLINARY CONSENSUS

    by Alexandre Ferreira Oliveira, Rafael Soares Nunes Pinheiro, Renata D’ALpino Peixoto, Munir Murad Júnior, Joaquim Maurício da Motta-Leal-Filho, Marcos Roberto de Menezes, Cristina Melo Rocha, Guilherme Lopes Pinheiro Martins, Agnaldo Soares Lima, Marcelo Bruno Rezande, et al.

    Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and represents a growing public health challenge. Aims: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of HCC. Methods: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early detection strategies. Recommendation statements were informed by a comprehensive, non-systematic review of the literature conducted using PubMed, Scopus, and the Cochrane Library. Results: Eighteen recommendations reached consensus, covering three main domains: (1) Primary prevention, including HBV vaccination, timely antiviral therapy for viral hepatitis, and lifestyle interventions for metabolic dysfunction. (2) Secondary prevention, outlining risk-based surveillance strategies for patients with advanced fibrosis or cirrhosis due to HBV, HCV, or MASLD. (3) Operational standards for surveillance, emphasizing ultrasound as the cornerstone of monitoring, the importance of structured reporting, management of small nodules, and the selective use of cross-sectional imaging. Conclusions: These multidisciplinary recommendations provide practical, adaptable guidance for HCC prevention, surveillance, and early detection. This guidance document aims to reduce the burden of HCC and support better clinical outcomes across diverse healthcare settings.

  • Open Access

    Diagnosis, clinical assessment, and staging of hepatocellular carcinoma: a Brazilian multidisciplinary consensus

    by Felipe José Fernández Coimbra, André Luís de Godoy, Paulo Henrique de Sousa Fernandes, Heládio Feitosa Neto, Rodrigo Nascimento Pinheiro, Ilka de Fátima Santana Ferreira Boin, Wellington Andraus, Francisco Tustumi, Paulo Cezar Galvão Do Amaral, Carlos Eduardo Brandão Mello, et al.

    Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a rising incidence largely driven by chronic liver disease. Accurate diagnosis and appropriate clinical assessment at the time of presentation are essential, as therapeutic strategies and prognosis depend on tumor burden, liver function, portal hypertension, and patient performance status. Aim: To develop evidence-based, multidisciplinary recommendations to guide the diagnosis, clinical assessment, and staging of patients with HCC. Methods: This consensus was developed by 43 experts from surgical oncology, hepatology, clinical oncology, radiology, interventional radiology, pathology, liver transplantation, gastroenterology, radiation oncology, and palliative care, under the coordination of the Brazilian Society of Surgical Oncology and 13 collaborating national medical societies. A scientific steering committee predefined clinically relevant questions addressing radiological and histopathological diagnosis, clinical assessment, diagnostic work-up, management of patients at the time of HCC diagnosis, and staging. These questions were discussed and refined in multidisciplinary meetings and submitted to structured voting rounds. Results: The panel formulated 18 recommendations covering key aspects of HCC evaluation, including standardized application of Liver Imaging Reporting and Data System (LI-RADS®) for imaging-based diagnosis, management of indeterminate lesions, indications for biopsy, histopathological classification and reporting, immunohistochemical markers, assessment of hepatic function and portal hypertension, staging systems, diagnostic work-up, and the role of multidisciplinary care. The recommendations emphasize integration of imaging findings with liver-related factors and clinical context to support individualized decision-making. Conclusions: This multidisciplinary consensus provides practical, evidence-based recommendations for the diagnosis, clinical assessment, and staging of HCC. By promoting standardized diagnostic practices while reinforcing comprehensive patient evaluation and multidisciplinary management, this document aims to improve diagnostic accuracy, optimize treatment selection, and support safe care.

  • Open Access

    Brazilian consensus- and evidence-based recommendations in the diagnosis and treatment of pancreatic exocrine insufficiency in patients after digestive surgeries. Position paper of six brazilian medical societies of surgery

    by Andre Luis Montagnini, Wanderley Marques Bernardo, Paulo Kassab, Claudemiro Quireze Junior, Cassio Virgílio Cavalcante de Oliveira, Alessandro Landskron Diniz, Rodrigo Nascimento Pinheiro, Alexandre Ferreira Oliveira, Pedro Portari Filho, Guilherme de Andrade Gagheggi Ravanini, et al.

    SciELO Preprints Collection is an integral part of SciELO, an international cooperation program aiming at the development of open access scientific communication covering all areas of knowledge. It operates as a collection of non-peer-reviewed manuscripts within the SciELO Network of national and thematic collection of journals. Background: Pancreatic exocrine insufficiency (PEI) is a condition characterized by reduced exocrine secretion, leading to decreased food digestion, and digestive tract surgeries can be a cause. Postoperative de novo PEI is defined as the onset of digestive symptoms following surgeries, which show significant improvement after the initiation of pancreatic enzyme replacement therapy (PERT). The diagnosis of postoperative PEI may be delayed due to mild or nonspecific symptoms, both in pancreatic surgeries and in upper abdominal surgeries. Aims: The aim of this study was to conduct a systematic review on the diagnosis and treatment of de novo PEI related to digestive surgeries, in collaboration with the development of a consensus among the main surgical societies in Brazil. Methods: The steering committee developed 10 questions related to two areas of interest: diagnosis and treatment. A systematic review was conducted for each of the domains. The evidence was assessed for quality using the GRADEpro tool. Recommendations were formulated for each of the questions. The final report was reviewed by representatives of the surgical societies for the consolidation and approval of the recommendations through a modified Delphi system. Results: De novo PEI should be considered in case of the onset of postoperative digestive symptoms. Diagnostic methods vary in complexity of execution, with varying sensitivity and specificity in the postoperative condition. Fecal Elastase-1 (FE-1) has limited value in diagnosing PEI in the postoperative setting. PERT can be initiated based on clinical suspicion, and there is no difference in approach regarding the type of surgery performed. PERT should be started at the appropriate dose for the intensity of symptoms and adjusted up or down according to symptom control. Proper treatment of PEI leads to symptom improvement and an increase in quality of life. PERT should be maintained as long as patients have a favorable clinical response. Conclusions: The recommendations encompass the diagnosis and treatment of de novo EPI and can serve as a basis for the establishment of educational programs led by the participating surgical societies.

  • Open Access

    MELANOMAS, SARCOMAS, AND RENAL METASTASES IN THE LIVER: HOW TO TREAT?

    by Angelica Maria Lucchese, Antonio Nocchi Kalil, Alessandro L. Diniz, Karl J. Oldhafer, Timothy M. Pawlik, René Adam, Olivier Soubrane, Maria Ignez Braghiroli, Ricardo Lemos Cotta-Pereira, International Hepato-Pancreato-Biliary Association

    Liver metastases from melanomas, sarcomas, and renal tumors are less frequent. Treatment and prognosis will depend on whether they are isolated or multiple, size and location, the presence or absence of extrahepatic neoplastic disease, age, stage of the initial disease, initial treatments instituted, time of evolution, and clinical condition of the patient. Recently, a high number of oncological therapies including monotherapy or in combination, neoadjuvants or adjuvants, and immuno-oncological treatments have been developed and tested, increasing disease-free time and survival.


  • Open Access

    BRAZILIAN CONSENSUS ON INCIDENTAL GALLBLADDER CARCINOMA

    by Felipe Jose F Coimbra, Orlando Jorge M Torres, Ruslan Alikhanov, Anil Agarwal, Patrick Pessaux, Eduardo de Souza M Fernandes, Claudemiro Quireze-Junior, Raphael Leonardo C Araujo, André Luis Godoy, Fabio Luis Waechter, et al.

    Background: Incidental gallbladder cancer is defined as a cancer discovered by histological examination after cholecystectomy. It is a potentially curable disease. However, some questions related to their management remain controversial and a defined strategy is associated with better prognosis. Aim: To develop the first evidence-based consensus for management of patients with incidental gallbladder cancer in Brazil. Methods: Sixteen questions were selected, and 36 Brazilian and International members were included to the answer them. The statements were based on current evident literature. The final report was sent to the members of the panel for agreement assessment. Results: Intraoperative evaluation of the specimen, use of retrieval bags and routine histopathology is recommended. Complete preoperative evaluation is necessary and the reoperation should be performed once final staging is available. Evaluation of the cystic duct margin and routine 16b1 lymph node biopsy is recommended. Chemotherapy should be considered and chemoradiation therapy if microscopically positive surgical margins. Port site should be resected exceptionally. Staging laparoscopy before reoperation is recommended, but minimally invasive radical approach only in specialized minimally invasive hepatopancreatobiliary centers. The extent of liver resection is acceptable if R0 resection is achieved. Standard lymph node dissection is required for T2 tumors and above, but common bile duct resection is not recommended routinely. Conclusions: It was possible to prepare safe recommendations as guidance for incidental gallbladder carcinoma, addressing the most frequent topics of everyday work of digestive and general surgeons.


  • Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)?

    by Márcio C Marques, Héber S. C. Ribeiro, Wílson L. Costa, Victor Hugo F. de Jesus, Mariana P. de Macedo, Alessandro L. Diniz, André L. Godoy, Igor C. Farias, Samuel Aguiar, Rachel S. P. Riechelmann, et al.

    Background and Objectives: Recent studies have suggested that sidedness of origin from colorectal adenocarcinomas is a predictor of survival, however the impact of this factor in patients with resected colon cancer liver metastases (CLM) is not clear. So, in this study, we compared clinic and pathologic characteristics and long‐term survival of patients with resected CLM according to the primary tumor location.Methods: This is a retrospective analyzes of a prospective database. Patients with resected CLM from 1998 to 2012 were included. Right colon included tumors from cecum to middle transverse colon, and left colon included tumors from splenic flexure to sigmoid.Results: One hundred fifty‐one patients were included, 27 right colon and 124 left colon. In the latter group, there were more patients with synchronous disease (67.7 × 6.2%, P = 0.026) and a higher CEA (22.0 × 11.7 ng/mL, P = 0.001). However, K‐Ras mutation was more frequent in right sided tumors (75.0 × 24.1%, P = 0.001). There was no difference in long term survival in both groups in this series even when adjusted for the confounding variables.Conclusion: Sidedness do not seem to be a predictor of long term survival in patients with resected colon cancer liver metastases.